Business Investment Opportunities

The company develops software that helps doctors and medical practitioners create quick and efficient clinical notes. - It also offers an AI interpreter that provides live suggestions for the notes without disrupting the clinical workflow. - The company currently has two customers and began generating revenue two months ago, so there is no prior-year revenue to report. - The revenue model is subscription-based. - The company is registered as an LLP.

Focus on the invention, manufacturing, and sales of an advanced oral screening device. - It is designed for use across all age groups, from 8 years to 80+ years. - The device enables comprehensive screening of the oral cavity to safeguard overall health. - We recently initiated operations in this innovative healthcare segment. - We have introduced three flexible business models: - Outright sales for ownership. - Rental basis for affordable access. - Pay-per-use model for cost-effective, on-demand usage.

This global biotechnology company specializes in cutting-edge allogeneic adult stem cell technology, uniquely positioned as the only FDA-approved entity worldwide, with the Drug Controller General of India (DCGI) approval in process. - The company manufactures clinical-grade stem cells under cGMP standards, providing vital materials for US-based and international clinical trials, hence establishing a strong foothold in the biotechnology sector. - With Investigational New Drug Approvals for several serious conditions, including acute myocardial infarction, chronic heart failure, and Alzheimer’s disease, the company focuses on innovative solutions for chronic ailments lacking effective treatments. - Its cell-based therapies are designed to enhance longevity and quality of life, particularly targeting rehabilitation for chronic stroke patients and those affected by diseases without available cures. - Operating for 24 years in California, the business has a robust track record and is actively seeking expansion opportunities in international markets, allowing for broader reach and impact. - Revenue is generated through multiple channels, including a sale of license model with annual royalty fees averaging around 15% revenue, alongside direct sales of stem cells to existing licensees that partner with hospitals and healthcare providers. - Major license sale deals over the years include up to $529 million with South Asian countries, $72 million with a Chinese firm, $21 million with a Mexican company, $20 million with a Russian entity, and $21 million with a Kazakh company, showcasing strong demand and financial viability. - As a result of focused and aggressive marketing efforts to sell licenses, our sales have increased by a wide margin. We expect to reach an annual turnover of USD 3 billion for the next CY. - Recently registered as a public limited company in India, the firm is planning to establish a local laboratory and operations, further strengthening its market presence in the biotechnology industry. - The workforce comprises around 50 full-time employees, supplemented by freelance and interns, enhancing operational flexibility and innovation in research and development. - The promoter is currently in India and oversees operations across both locations.

Proposed undergraduate medical college offering Bachelor’s in Unani Medical Science (BUMS) program. - Initial intake capacity planned at 100 seats, with expansion target to 400 seats within 4 years. - Project currently in pre-operational stage, seeking funding for construction and infrastructure development. - Revenue model based on tuition fees from undergraduate medical students. - Led by a promoter with 30 years of experience in the education industry. - Positioned to address growing demand for alternative and traditional medical education. - Affiliation from the Medical Council of India to be obtained post completion of construction and compliance requirements. - Opportunity to establish a scalable Unani medical institution with phased seat expansion.

We are an online platform engaged in the delivery of grocery, personal hygiene and everyday essential items. - We also do online food delivery and have more than 10 restaurants registered with us. - As on date, we have more than 300 registered users. - Users can place orders on our website and on the mobile app. - Over 5,000 users have downloaded the app on the Google Play Store and it has an average rating of more than 4 stars. - 60% of revenue is generated by food delivery and the remaining 40% by our online supermarket business. - We have 5 commercial bikes for delivery services. - Currently, we only operate in Mecheda and we plan to expand our delivery to other locations.

We are partners of a large chemicals manufacturer who is a market leader with 49% market share in east European market. - Distribute their range of products in India and in the Middle East under a separate entity. - Our commodities are environmentally sustainable and bio-degradable. - Have 6 distributors all over India with 10 more in the pipeline. - We also have clients who are reputed companies such as Nestle, Natural Ice Cream, and other such large brands. - Promoter has over 6 years of experience working in the field of cleaning and hygiene chemicals. He has invested over INR 9 crore in the development of this business. - Our run rate sales were reduced due to Covid but now onward seeing the Indian green chemical growth we will achieve ore covid sales in this year only.

1. Multi-brand laser aesthetic clinic network operating in 14 cities across Estonia, Lithuania, Latvia and Poland, built on a clustered, capital-efficient footprint. 2. Recurring-revenue model: membership and prepaid subscriptions deliver high retention and visibility on future cash flow, not one-off transactions. 3. Proprietary technology asset — a centralized operating system (booking, CRM, HR management, finance, sales and marketing analytics on a BigQuery/Power BI data stack) that standardizes operations across all locations and is licensable as a stand-alone product. 4. Active vertical expansion into licensed medical aesthetics, moving the network up the value chain to higher average ticket and stronger margins. 5. Improving profitability: revenue growing year-over-year with rising operating margin as overhead is optimized and the medical mix scales. 6. Led by a founder with 10+ years building and operating multi-country aesthetic clinic networks, supported by a maturing management team that reduces owner dependence.